医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

LianBio Appoints Pascal Qian as General Manager of China

2021年08月02日 PM09:00
このエントリーをはてなブックマークに追加


 

SHANGHAI & PRINCETON, N.J.

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.

“With more than 25 years of experience in the industry, including a robust track record of leading successful drug launches, we are confident that Pascal will play a critical role in developing our China business strategy, building upon our China operations and the infrastructure to develop and commercialize our products,” said Konstantin Poukalov, Managing Director, Perceptive Advisors and Executive Chairman, LianBio. “We are proud to have Pascal join our team as we continue to work diligently to bring innovative medicines to patients in the years to come.”

Mr. Qian has extensive experience launching products in China, including Verzenio, Tyvyt, Elunate, Afinitor, Votrient, Sutent, Vfend and Singulair. He has also led new product development initiatives in China for multiple globally developed drugs, including crizotinib, axitinib and palbociclib.

Mr. Qian most recently served as the Vice President, Head of Oncology Business Unit, at Lilly China. In this capacity, he oversaw a more than 700-person China Oncology BU team and was responsible for the group’s P&L and organizational development. Prior to Lilly, Mr. Qian held roles at Novartis from 2012 until 2018, ultimately serving as Executive Director, BU Head of Solid Tumor at Novartis Oncology. From 2005 until 2012, he served in several key roles of increasing responsibility at Pfizer, including Business Liaison Head, Global Clinical Development and Medical Affairs, and China Oncology Business Unit Head.

Mr. Qian graduated from Shanghai Jiaotong University Medical Institute (Shanghai 2nd Medical University).

About LianBio

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and other major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics. For more information, please visit www.lianbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005297/en/

CONTACT

For investor inquiries, please contact:

Elizabeth Anderson, VP Communications and Investor Relations

E: elizabeth.anderson@lianbio.com

T: +1 646 655 8390

For media inquiries, please contact:

Tyler Gagnon, CanaleComm

E: tyler.gagnon@canalecomm.com

T: +1 508 904 9446

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024